W
Weidong Xiong
Researcher at University of California, Los Angeles
Publications - 33
Citations - 1635
Weidong Xiong is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Genetic enhancement & Transgene. The author has an hindex of 19, co-authored 33 publications receiving 1551 citations. Previous affiliations of Weidong Xiong include Cedars-Sinai Medical Center & University of Manchester.
Papers
More filters
Journal ArticleDOI
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
James F. Curtin,James F. Curtin,Naiyou Liu,Naiyou Liu,Marianela Candolfi,Marianela Candolfi,Weidong Xiong,Weidong Xiong,Hikmat Assi,Hikmat Assi,Kader Yagiz,Kader Yagiz,Matthew R. Edwards,Kathrin S. Michelsen,Kurt M. Kroeger,Kurt M. Kroeger,Chunyan Liu,Chunyan Liu,A.K.M. Ghulam Muhammad,A.K.M. Ghulam Muhammad,Mary C. Clark,Mary C. Clark,Moshe Arditi,Begonya Comin-Anduix,Antoni Ribas,Pedro R. Lowenstein,Maria G. Castro +26 more
TL;DR: Evidence is provided for the molecular and cellular mechanisms that support the rationale for the clinical implementation of antibrain cancer immunotherapies in combination with tumor killing approaches in order to elicit effective antitumor immune responses, and thus, will impact clinical neuro-oncology practice.
Journal ArticleDOI
Regulatable Gene Expression Systems for Gene Therapy Applications: Progress and Future Challenges
Shyam Goverdhana,Mariana Puntel,Weidong Xiong,Jeffrey M. Zirger,Carlos Barcia,James F. Curtin,E. B. Soffer,Sonali Mondkar,Gwendalyn D. King,Jiang Hu,Sandra A. Sciascia,Marianela Candolfi,Diana S. Greengold,Pedro R. Lowenstein,Maria G. Castro +14 more
TL;DR: The main regulatable systems currently under development, the gene transfer systems employed for their expression, and also the preclinical models in which they have been used successfully are highlighted and the substantial challenges that still remain are discussed.
Journal ArticleDOI
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model
Sumia Ali,Gwendalyn D. King,James F. Curtin,Marianela Candolfi,Weidong Xiong,Chunyan Liu,Mariana Puntel,Queng Cheng,Jesús Prieto,Antoni Ribas,Jerzy W. Kupiec-Weglinski,Nico van Rooijen,Hans Lassmann,Pedro R. Lowenstein,Pedro R. Lowenstein,Maria G. Castro,Maria G. Castro +16 more
TL;DR: It is proposed that combined Flt3L and HSV1-TK adenoviral-mediated gene therapy may provide an effective antiglioma treatment with increased efficacy in clinical trials of glioma.
Journal ArticleDOI
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
Marianela Candolfi,Kader Yagiz,David Foulad,Gabrielle E. Alzadeh,Matthew Tesarfreund,A.K.M. Ghulam Muhammad,Mariana Puntel,Kurt M. Kroeger,Chunyan Liu,Sharon Lee,James F. Curtin,Gwendalyn D. King,Jonathan Lerner,Katsuaki Sato,Yohei Mineharu,Weidong Xiong,Pedro R. Lowenstein,Maria G. Castro +17 more
TL;DR: The results indicate that Ad-TK+GCV+Ad-Flt3L exhibit the highest efficacy and safety profile among the several proapoptotic approaches tested.
Journal ArticleDOI
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics
Marianela Candolfi,Weidong Xiong,Kader Yagiz,Chunyan Liu,Akm Ghulam Muhammad,Mariana Puntel,David Foulad,Ali Zadmehr,Gabrielle E. Ahlzadeh,Kurt M. Kroeger,Matthew Tesarfreund,Sharon Lee,Waldemar Debinski,Dhruv Sareen,Clive N. Svendsen,Ronald Rodriguez,Pedro R. Lowenstein,Maria G. Castro +17 more
TL;DR: A regulatable adenoviral vector encoding a mutated human IL-13 fused to Pseudomonas exotoxin that specifically binds to IL13Rα2 to provide sustained expression, effective anti-GBM cytotoxicity, and minimal neurotoxicity is developed, representing a significant advance in the development of targeted therapeutics for GBM.